IL6R and rheumatoid arthritis: This systematic review and meta-analysis investigated the efficacy and safety of the newly approved JAK inhibitors, namely, baricitinib and upadacitinib, as well as the IL-6R inhibitor, sarilumab, in patients with moderately-to-severely active RA and inadequate response to or intolerance of csDMARDs.